← Patent-cliff monitor small molecule SPRAVATO ESKETAMINE HYDROCHLORIDE
Loss of exclusivity February 2040 latest FDA-listed patent expiry
Drug detail Brand name SPRAVATO Active ingredient ESKETAMINE HYDROCHLORIDE Strength EQ 28MG BASE Dosage form SPRAY Route NASAL Modality Small molecule FDA approval March 2019 Marketing status RX
Listed patents Patent Expires Type 11883526 February 2040 use U-3813 10869844 September 2035 use U-3036 11173134 September 2035 use U-3257 11311500 September 2035 use U-3035 11446260 March 2034 use U-3446 8785500 March 2033 use U-4112 9592207 March 2027 use U-4112
Regulatory exclusivity Code Expires I-959 January 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.